One To Watch

Zydus Lifesciences

Company Overview

A fully integrated Indian multinational pharmaceutical company headquartered in Ahmedabad, Zydus Lifesciences operates across generics, biosimilars, and novel drug discovery with a growing international footprint. Formerly known as Cadila Healthcare Limited, the company rebranded to Zydus Lifesciences and ranks among India's four largest pharmaceutical companies. Its capabilities span the full pharmaceutical value chain, from active ingredient manufacturing through to branded formulations, biologics, and innovative drug development. The company ranked 100th on the Fortune India 500 list in 2020 and maintains a significant presence in the US generics market.

Headquarters and Global Presence

Zydus Lifesciences is headquartered in Ahmedabad, Gujarat, India, with its US operations managed from a dedicated North American business unit. The company has manufacturing facilities across India and, following its 2025 collaboration with Agenus, is expanding biologics manufacturing capacity in California, USA.

Founding and History

Zydus Lifesciences was founded in 1952 by Ramanbhai Patel and has grown from a domestic Indian generics maker into a global healthcare group. The company operated for decades under the Cadila Healthcare name before formally rebranding to Zydus Lifesciences. Key milestones include listing on Indian stock exchanges under the ticker ZYDUSLIFE and a sustained push into the US generics market. In October 2023, the company appointed Punit Patel as President and CEO to lead its North American business operations.

Therapy Areas and Focus

Zydus Lifesciences operates across a broad therapeutic canvas including metabolic and endocrine diseases, oncology, infectious diseases, and immunology. Its novel drug pipeline has a pronounced focus on liver disease and metabolic disorders, where saroglitazar has achieved regulatory designations in the United States. In oncology, the company is expanding through biosimilar development targeting high-value biologics such as pertuzumab and pembrolizumab. The company also participates in immuno-oncology through its collaboration with Agenus on the BOT/BAL checkpoint inhibitor combination.

Technology Platforms and Modalities

Zydus deploys multiple drug modalities simultaneously, including small molecules, monoclonal antibodies, biosimilars, and prophylactic vaccines. Its novel drug discovery engine has produced saroglitazar, a liver-selective dual PPAR alpha/gamma agonist developed as an oral small molecule. On the biologics side, the company's Zydus Biologics division manufactures biosimilar monoclonal antibodies and is scaling US-based biologics manufacturing capacity through the Agenus asset acquisition. The combination of generics volume and a proprietary innovation engine positions Zydus as a hybrid model within the Indian pharma landscape.

Key Pipeline and Programs

Saroglitazar is the company's most advanced novel asset, a liver-selective dual PPAR alpha/gamma agonist administered orally. It has received both Fast Track designation and Orphan Drug Designation from the FDA for primary biliary cholangitis (PBC), positioning it in a rare liver disease segment with limited treatment options. The drug is also being investigated for non-alcoholic steatohepatitis and related metabolic liver conditions.

BOT/BAL is a checkpoint inhibitor combination in-licensed from Agenus under a $141 million strategic collaboration announced in 2025. Zydus secured exclusive rights for BOT/BAL in India and Sri Lanka, alongside a $16 million equity investment in Agenus at $7.50 per share, and is acquiring Agenus's California manufacturing facilities for $75 million upfront plus $50 million in contingent payments.

Sigrima is Zydus's biosimilar of Roche's pertuzumab (Perjeta) targeting HER2-positive breast cancer. It was launched in India, although a Delhi High Court ruling in July 2024 temporarily barred its sale following a challenge from Roche. Additionally, through a separate licensing agreement with Formycon, Zydus holds rights to commercialize a biosimilar of pembrolizumab (Keytruda) in the US and Canada.

Recent Developments

In early 2025, Zydus and Agenus closed a $141 million strategic collaboration covering the BOT/BAL immuno-oncology program, a California manufacturing asset acquisition, and an equity stake in Agenus. Separately, Zydus and Formycon entered an exclusive partnership for the licensing and supply of a pembrolizumab biosimilar for the US and Canadian markets. In July 2024, the Delhi High Court temporarily restrained Zydus from selling Sigrima, its pertuzumab biosimilar, following litigation initiated by Roche. The company formally completed its rebranding from Cadila Healthcare to Zydus Lifesciences, a transition confirmed publicly in mid-2024.

Key Personnel

Pankaj R. Patel serves as Chairman of Zydus Lifesciences, having guided the group's strategic evolution from a domestic generics business into a diversified global healthcare company. Sharvil P. Patel serves as Managing Director and has been central to driving the company's innovation agenda and international expansion. Punit Patel was appointed President and CEO of the North America business in October 2023, tasked with leading US generics and biologics commercial operations.

Strategic Partnerships

The most significant recent alliance is the $141 million collaboration with Agenus, covering BOT/BAL rights in India and Sri Lanka, a manufacturing asset transfer in California, and a direct equity investment. Zydus also signed an exclusive licensing and supply agreement with Germany's Formycon for a pembrolizumab biosimilar intended for the US and Canadian markets. These partnerships mark a deliberate shift toward biologics manufacturing and immuno-oncology capability-building alongside the company's established generics base.

FAQ Section

Zydus is executing a dual strategy of defending its generics leadership while building a biologics and novel drug capability. The $141 million Agenus collaboration and the Formycon pembrolizumab biosimilar deal both signal serious investment in the biologics value chain. Internally, the saroglitazar program demonstrates the company's ambition to originate and develop novel chemical entities capable of receiving FDA designation status.

Saroglitazar acts as a dual agonist of PPAR alpha and PPAR gamma receptors, two nuclear receptors that regulate lipid metabolism and insulin sensitivity. Activating both pathways simultaneously addresses the metabolic dysfunction and hepatic inflammation underlying conditions like primary biliary cholangitis and NASH. Its liver-selective profile is designed to concentrate efficacy at the target organ while limiting systemic side effects historically associated with PPAR agonists.

Zydus is building domestic manufacturing capability for complex biologics rather than relying solely on contract or licensed supply, as evidenced by the Agenus California facility acquisition. Licensing in late-stage biosimilar assets from European developers like Formycon accelerates time to market in the US without requiring full in-house development cycles. This asset-light licensing model combined with owned manufacturing infrastructure creates a more defensible commercial position than pure generics copying.

Saroglitazar holds both FDA Fast Track designation and Orphan Drug Designation for the treatment of primary biliary cholangitis, a rare autoimmune liver disease with limited approved therapies. These designations facilitate accelerated FDA review and provide market exclusivity incentives if approval is achieved. The drug's investigational status in the US means it remains in clinical evaluation, with the PBC indication representing the primary near-term regulatory pathway.

Metabolic and liver diseases anchor the novel drug pipeline, with saroglitazar targeting PBC and metabolic liver conditions. Oncology is the other principal axis, addressed through biosimilars of pertuzumab and pembrolizumab as well as the Agenus BOT/BAL immuno-oncology program. Infectious diseases and immunology also feature across the broader portfolio, reflecting the company's origins as a diversified pharma manufacturer with over 211 active clinical trials on record.

Zydus is a mature, revenue-generating generics business simultaneously running an early-to-mid stage novel drug pipeline. Saroglitazar represents the most advanced proprietary asset in the US context, with FDA designations in place but approval pending clinical readouts. The Agenus and Formycon partnerships place the company at a manufacturing and commercialization build-out phase for biologics, with US market entry for the pembrolizumab biosimilar among the nearer-term commercial milestones.

Key watchpoints for Zydus Lifesciences include the following:

Saroglitazar clinical data and FDA interactions for the PBC indication, which could establish Zydus as a rare disease innovator in the US market.
Resolution of the Delhi High Court injunction over Sigrima (pertuzumab biosimilar), which determines whether Zydus can participate in India's growing HER2-targeted oncology biosimilar market.
Integration and ramp-up of the Agenus California manufacturing facility, which is central to the company's US biologics ambitions.
Regulatory progress on the Formycon-partnered pembrolizumab biosimilar in the US and Canada, one of the highest-value biosimilar opportunities in the pipeline.
Competitive pressure in US generics from pricing erosion and channel consolidation, which remains a structural risk for the company's core revenue base.

Want to Update your Company's Profile?